key: cord-1013854-sciay2xs
authors: Pichler, Daniel; Baumgartner, Matthias; Kimpel, Janine; Rössler, Annika; Riepler, Lydia; Bates, Katie; Fleischer, Verena; von Laer, Dorothee; Borena, Wegene; Würzner, Reinhard
title: Marked increase in avidity of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) antibodies 7-8 months after infection is not diminished in old age
date: 2021-06-04
journal: J Infect Dis
DOI: 10.1093/infdis/jiab300
sha: ceec750eba15233725ac0eca7e202cf51f393447
doc_id: 1013854
cord_uid: sciay2xs

The kinetics of IgG avidity maturation during severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection obtained from 217 participants of the Ischgl cohort, Austria, was studied 0.5-1.5 (baseline) and 7-8 months (follow up) after infection. The IgG avidity assay, using a modified IgG ELISA and 5.5 M urea, revealed that old age does not diminish the increase in avidity, detected in all participants positive at both time points, from 18% to 42%. High avidity was associated with a marked residual neutralization capacity in 97.2.% of participants (211/217), which was even higher in the older age group, revealing an important role of avidity assays as easy and cheap surrogate tests for assessing the maturation of the immune system conveying potential protection against further SARS-CoV-2 infections without necessitating expensive and laborious neutralization assays.

The RNA virus SARS-CoV-2 is a member of the severe acute respiratory syndrome-related coronavirus family, such as SARS-CoV-1 which was responsible for the SARS-outbreak in 2002-2003 [1] . Described for the first time in Wuhan, Hubei, China, as having originated from a seafood wholesale market at the end of December 2019, SARS-CoV-2 spread globally within a couple of months, attaining the status of pandemic by mid-March 2020 [2] . Since then, more than 122 million confirmed cases and more than 2.7 million deaths have been reported worldwide (as of: 26 .03.2021) [3] .The disease caused by the virus (COVID-19) is characterized by mild to moderate symptoms including dry cough, fever, fatigue and loss of smell and taste in the majority of cases [4, 5] . In various risk groups and especially older age groups, however, severe illnesses occur requiring hospitalization and intensive care unit (ICU) management with a death toll of 1-5% [4] .

Austria is with more than half a million cases (as of: 22 .03.2021), also among the countries hit by the pandemic [3] . The first cases reported in Austria were on February 25 th , 2020. The first significant outbreak of SARS-CoV-2 was described in Ischgl, Tyrol, at the beginning of March. On the 13 th March, the government placed the town of Ischgl under quarantine and on the 16 th of March the whole nation was locked down under the COVID-19 Measures Act 2020. The outbreak in the ski resort Ischgl played a major role in the spread of SARS-CoV-2 throughout Austria and Northern Europe [6] . An epidemiological cluster analysis carried out by the Austrian Agency for Health and Food Safety (AGES) showed that up to 40% of the Austrian SARS-CoV-2 infections by 20 th of April 2020 had their origins in Ischgl [7] . In total, 45% of the adult population had antibodies 0.5-1.5 months after the infection [8] .

As stringent preventive measures continue to curb the uncontrolled spread of the virus, it is of paramount importance to understand the hallmarks of immune response among the infected. A plethora of previous studies have shown that SARS-CoV-2 infection induces virus-specific antibodies and a marked T-cellular immune response. Whereas T-cell response helps prevent severe illnesses following an infection [9, 10] , antibodies (in particular neutralizing ones), bind specifically to viral targets blocking an entry into host cells, thus preventing a cell from becoming infected with the virus. For the latter, avidity diagnostics of antibodies are of particular value [11] . Avidity is the binding strength of an antibody-antigen complex and thus elucidates the quality of the immune response [12] . Generally speaking, the avidity is low at the beginning of an infection. After a maturation process that takes a couple of months, avidity increases and indicates a functionally active antibody pool, as shown for SARS-CoV-1 [13] . Now that recent data on longevity of the immune response to SARS CoV-2 prove persistence of antibodies over a period of 7-8 months [14] , characterizing the avidity of SARS-CoV-2 specific antibodies is of key interest. To date only few studies exist which have studied avidity, and only for a much shorter period.

The data from Ischgl 7-8 months after the initial infection [14] could represent a particular basis to understand aspects of the dynamics of the immune response to SARS-CoV-2 M a n u s c r i p t 4 infections due to the above mentioned, especially the high infection rate. Furthermore, the willingness to participate in this study was high. Nearly the whole town has taken part (83%) in the first survey in April 2020 [8] (baseline) and 217 informative adults were included in the second survey in November 2020 (follow up).

The main aim of the study was to assess in a large longitudinal study, with one of the longest follow up times currently available, whether the marked increase in avidity of antibodies we observed 7-8 months after an infection [14] was also substantial in old age. Other aims were to assess the dependence on sex and whether a high avidity is correlated with a high neutralization capacity, which would then convey an important role to avidity tests for assessing potential protection against further SARS-CoV-2 infections without necessitating expensive and laborious neutralization assays.

Our study population is a subpopulation of a large longitudinal seroprevalence study in Ischgl, Austria, targeting the entire adult population of Ischgl (n=1,527, at the time of data collection). Both the baseline and the follow up study were assessed by the local Ethics Committee of Medical University of Innsbruck (1100/2020, 21 Apr 2020 & 1330/2020, 27.10.20) . Informed consent was given by all participants. Blood was drawn at two time points, April 2020 (baseline) and November 2020 (follow up). We included all the 217 adults positive for anti-S1 IgG at both time points, only 6 of them reported a hospital stay due to SARS-CoV2 infection (Table 1) . Only eleven subjects (5%) of the baseline cohort presented with negligible antibody titres at follow up and could not be used for the calculation of avidity. All plasma samples were stored at +4°C for short term use, or at -20°C when stored for longer than 4 weeks.

Plasma samples were tested for antibody avidity by an Anti-SARS-CoV-2-ELISA (Euroimmun AG, Lübeck, Germany, REF: EI 2606-9601). Microplate wells coated with an S1-domain of the spike protein of SARS-CoV-2 were used in this study. The antigen was expressed recombinantly in the human cell line HEK 293 [15] . To determine the relative avidity index (RAI), two microplate wells next to each other were used for each subject. In one well the Anti-SARS-CoV-2-ELISA was carried out according to the manufacturer's instructions and in the other one an additional urea treatment (5.5 M for 10 minutes) was performed. The urea treatment leads to the detachment of the low-avidity antibodies from the antigen [13] . Plasma samples were initially diluted 1:101 in sample buffer. If the photometric measurement showed an extinction higher than 2.0 in the well without urea treatment, a higher dilution of 1:401, 1:801 or 1:1601 was used to bring the extinction into the linear range. Otherwise the ELISA was done according to manufacturer's instructions [15] . The relative avidity index (RAI) was calculated from the ratio of the absorbance with and without urea incubation and is expressed as percentage.

M a n u s c r i p t 5

The assay is based on a replication defective variant of the vesicular stomatitis virus (VSV), VSVΔG-GFP, as vector as described previously [16] . The virus was produced on 293T cells stably expressing the SARS-CoV-2 spike protein (Wuhan isolate), leading to single-cycle infectious virus particles pseudotyped with SARS-CoV-2 spike. Patient samples were incubated with the vector for 1 h at 37°C, in a four-fold serum dilution starting with a 1:16 dilution. Subsequently 293T-ACE2 cells, seeded the day before, were infected with the vector-serum-mixtures and incubated for 16 hours. Afterwards the plates were analyzed using an Immunospot reader (C.T.L. Europe, Bonn, Germany), in order to count the infected cells. 50% neutralization titers were calculated using a nonlinear regression as described previously [17] . In our study, samples with a neutralization titre ≥1:16 were considered as definitely neutralizing, samples which did not neutralize at 1:16, i.e. <1:16, were considered negative or not neutralizing [16] . Quantitative variables were compared across groups using parametric (Student's t-test and ANOVA) or non-parametric methods (Mann-Whitney U-test, Kruskal-Wallis test), where appropriate. Linear regression models were used to assess the relationship between difference in RAI at baseline and follow up by age and sex controlling for baseline RAI. Associations between categorical variables were tested using χ², with Fishers exact test where appropriate. A two-tailed value of p <0.05 was considered statistically significant for all comparisons.

Simple linear regression models for age and neutralization titer, and RAI (%) with neutralization titer, at both baseline and follow up, were fitted separately. For all regressions, neutralization titer variables were transformed using log 2 base, to meet the assumptions of the linear regression model and outliers were removed.

We observed increasing avidity during the observation period of 6.5 months from 18% to 42% was observed in all samples (217/217), which was independent of the age and certainly not impaired in older adults (Figure 1 , r=-0.09 at baseline and r=-0.1 at follow up). The only slight tendency of lower avidities with increasing age was aggravated by just one outlier (Figure 1 ; see arrow) and influenced by the smaller amount of data in very old age group (see limitations, in Discussion). We divided the cohort into three age groups, demonstrating a significant increase in avidity at 6.5 months post infection and comparable avidity in participants over 61 years of age (p<0.0001, for all three age groups). No significant lower avidity was detectable in older age groups (Figure 2, p>0.2) . There was also no significant difference in avidity between males and females, neither at baseline nor at follow up (Supplemental Figure 1 , p>0.1 at baseline and p>0.6 at follow up). M a n u s c r i p t 6 Association of avidity with residual neutralization capacity, which was even increased in old age at follow up Although there was a marked decrease in neutralization capacity at 6.5 months, 97.2% of all participant plasma samples had neutralizing capacity (≥1:16) (Figure 3 ). In univariate regression analyses no relationship was found between neutralization capacity and avidity at baseline, however at follow up, significantly association was found, a 2-fold increase in neutralization capacity was significantly associated with a 1.99 percentage point increase in RAI (95% CI 0.76 -3.22) (Figure 3) . There was only a slight significant difference in neutralization capacity between males (81/90) and females (121/127), only at baseline, but not at follow up (Supplemental Figure 2 ). Of note, the six samples with a negative neutralization titre (<1:16) still exhibited a marked avidity, not different from those positive for neutralizing antibodies (Figure 3, p>0. 2)

The effect of age on neutralization capacity was both significant and similar at baseline and follow up (Figure 4) . A one year increase in age was found to be associated with a 1.01 fold (1%) increase in neutralization capacity at baseline (95% CI 1.00 -1.02); at follow up, a one year increase in age was found to be associated with a 1.01 fold increase in NT (95% CI 1.01-1.02). Thus, neutralization capacity was not decreased, but even increased in the older age group.

Although there have been studies and indications in the past that avidity may rise weeks after active COVID-19 disease (detailed below), our present study on a subgroup of n=217 participants from a large cohort [14] , comprising all antibody positive subjects at both time points, clearly confirmed the rise of avidity and revealed that it is not only significant, but marked. The substantial increase in median avidity from 18% only 0.5-1.5 months after the onset of COVID-19 to 42% half a year later is clear evidence that robust immunity persists at least 7-8 months after an infection with SARS CoV-2. This immunity is sustained and not impaired in older participants.

The domain of avidity testing is clearly the assessment whether an infectious disease commenced very recently [18] . Antibodies developed shortly after a primary infection exhibit a low avidity and bind weakly to the specific antigenic target. Over time, affinity towards the antigen increases as antibodies 'mature' through clonal expansion, hypermutation and affinity selection in the germinal centre. This selection process guarantees an efficient immune defense in case of a repeated encounter with the pathogen. Aside from this, the time required to achieve a certain level of affinity maturation is utilized in clinical diagnostics to estimate the approximate time of a first time contact with the pathogen. Whereas antibodies with low binding affinity indicate a recent infection, a high binding affinity speaks of a primary infection that took place at least 3-4 months ago. This is of particular importance in pregnancy, where a primary infection plays a major role in intrauterine infection which is especially relevant for rubella infections [18] : a high avidity of IgG antibodies in the first weeks of pregnancy, without medical history of a transfusion, would then clearly point M a n u s c r i p t 7 towards an onset of the infection months before the pregnancy, even in the presence of positive IgM, implying that the unborn cannot be affected by this infection, thus avoiding an unnecessary termination of pregnancy.

In order to assess the immune response, avidity will provide important and additional information on the immune response, revealing functionality of the persisting antibodies. Concerning the time course, the group of Liu found that IgG against SARS-CoV-2 S1 and receptor binding domain showed a low avidity 6-45 days post infection [19] , comparable to the 18% obtained during our baseline. Benner and coworkers found that anti-spike IgG avidity increased over days post symptom onset and appeared to peak around day 21 before beginning to plateau [20] . Our data could not elucidate when the peak of avidity has been reached, but there was an overall increase from 18% to 42% and there is thus the possibility that the maximum was even higher, as Benner and colleagues have also shown a decrease in their, only hospitalized, patients. In contrast, Luo and coworkers found that IgG avidity significantly increases from 1-90 days post symptom onset, without indications of a decrease [21] . Our study demonstrates continued avidity at 7-8 months post infection. Given the fact that a high proportion of anti-S antibodies are neutralizing in nature, a stronger binding affinity of these antibodies corroborate the assumption that an efficient immune defense normally persists at least 7 months after an initial infection with SARS CoV-2.

Concerning avidity in old age in other infectious diseases, antibody response to influenza vaccination in older people has been shown to be considerably lower than in younger adults [22] , but age affects quantity, but not quality of antibody responses after vaccination against tick-borne encephalitis [23] . Despite their overall impairment of immune functions seniors are still able to produce high-affinity antibodies that have similar functional activities as those produced in young age [23] . Others claim that the reduction in number and size of germinal centers, where antibody affinity maturation processes, leads to a decrease of antibody affinity [24] . Along the same line, Banerjee and co-workers argue that older people are less able to make high-affinity antibodies to foreign antigens [25] . For pertussis, avidity against filamentous haemagglutinin was lower in the seniors, whereas there was no significant difference for avidity against the toxin [26] .

For COVID-19 patients, higher levels of anti-spike avidity were associated with older age, male sex, and hospitalization [20] . This may be the case because males have increased disease severity compared to females. Additionally, increased risk for severity of disease is associated with advancing age, resulting in a more severe form of COVID-19 and therefore in a higher anti-spike IgG titre and avidity [20] . This was corroborated by another study detailing that avidity was significantly higher in severe than mild disease cases [21] . In our cohort there was no stronger avidity in old age or males, but most of our study population was less severely affected by COVID-19 [8] . On the other hand, it is of public health interest to characterize the quality of immune response among the majority of a population, known to acquire normally mild or asymptomatic, rather than severe SARS-CoV-2 infection. For the same reason as a limitation of our study, namely that we do have older participants (60-80 years), but not very old ones (>80 years), may not be too serious, as not the relative death M a n u s c r i p t 8 toll, but the total number is higher among the 60-80 years old compared to the >80 years old [6] .

In addition to antibody binding avidity, neutralization capacity is also an important marker of immune response. Higher levels of anti-spike IgG titres and higher levels of anti-spike IgG avidity were significantly associated with a higher prevalence of a neutralizing antibody titre [20] . However, those who generated a high neutralizing antibody titre still had high neutralizing antibody titres after three months, with only a negligible decline [27] . Only 5% of the original cohort ((11 subjects, not included here) did not have sufficient antibody concentrations for calculation of avidity and another 2.8% of the baseline cohort (6 subjects) presented with a non-detectable neutralization capacity at follow up. This implies that more than 92.5% of the baseline antibody-positive cohort neutralized at follow up after 6.5 months.

As a rise in avidity confirms the maturation of the entire immune system, detailed above, we propose that the high avidity will likely compensate for a slight decrease in neutralization activity. Even more, given that neutralization capacity is just an in vitro surrogate marker, although an important one, the proof of a strong avidity of antibodies, confirming that the immune system has matured, may even be a better universal immunologic parameter to predict a protection from a re-infection, especially after almost three quarters of a year.

It is of interest to note that elderly and middle-age patients have been found to have significantly higher plasma neutralizing antibodies than young patients [28] , which was also found in our study. The former samples were collected from 175 COVID-19 recovered patients with mild symptoms 10-24 days after symptom onset [28] . Even higher numbers may be found in patients having severe symptoms, as those with lower disease severity were reported to show a decline to undetectable neutralizing antibodies [27] . Likewise, individuals who recover from COVID-19 without becoming hospitalized typically do not have high neutralizing antibody activity [20] and individuals with severe disease exhibited elevated virus-neutralizing titres [29] . Ripperger and colleagues have also confirmed that disease severity correlates with the neutralization capacity, but they did not find a correlation of age or sex, despite the difference in outcome [29] . Again, we cannot draw precise conclusions on associations with disease severity, but at baseline we had many participants with high neutralization titres (Figure 3 ), although only a few participants in the cohort had been hospitalized. Interestingly, although old male patients are more seriously affected by COVID-19, we did not see a gender difference in our big cohort for avidity and only a weak one for neutralization and only at baseline. M a n u s c r i p t 9 Studies investigating the sustainability of neutralization have shown a prolonged immunity over six months. The authors conclude that these individuals could mount a rapid and effective response to the virus upon re-exposure [30] . This is corroborated by Ripperger and colleagues who showed that neutralizing antibodies are stably produced for at least 5-7 months after SARS-CoV-2 infection [29] ,T and also supported by our study, showing a neutralization capacity for more than 7 months post infection, although titres decrease. In summary, it is very interesting that older people can mount a similar avidity than the young and that the assessment of avidity may actually represent an excellent surrogate marker for a sustained immunity, replacing the laborious and expensive tests neutralization assays. A follow up study over an even longer time period may confirm our findings, in particular that high avidity is a better and more universal marker indicating protection from infection. M a n u s c r i p t 14 Legends to Figures   Figure 1. Correlation between age and relative avidity indices (RAI, %) plotted against age at baseline and at follow up with Spearmans correlation coefficient (r). Green squares represent RAIs of participants obtained at baseline (0.5-1.5 months after infection). Blue circles show RAIs of the same participants at follow up (7-8 months after infection). The lower dashed line shows mean RAIs across age at baseline, the upper continuous line the mean RAIs across age at follow up, n=217. The arrow indicates one outlier. 

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

A Novel Coronavirus from patients with pneumonia in China

Coronavirus Disease (COVID-19) Dashboard

Clinical characteristics of coronavirus disease 2019 in China

Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and metaanalysis

Emergence of coronavirus disease 2019 (COVID-19) in Austria

AGES zur epidemiologischen Abklärung des Cluster S

Accessed 26

High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients

The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity)

Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination

Antibody avidity maturation during severe acute respiratory syndrome-associated coronavirus infection

Follow-up study in the ski-resort Ischgl: Antibody and T cell responses to SARS-CoV-2 persisted for up to 8 months after infection and transmission of virus was low even during the second infection wave in Austria

ELISA (IgG): Instructions for use

Comparison of Four SARS-CoV-2 Neutralization Assays

Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis

Diagnosis of recent primary rubella virus infections: significance of glycoprotein-based IgM serology, IgG avidity and immunoblot analysis

Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates

SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors

Kinetics of SARS-CoV-2

Antibody Avidity Maturation and Association with Disease Severity

Antibody response to influenza vaccination in the elderly: a quantitative review

Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis

Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity

Age-and tissuespecific differences in human germinal center B cell selection revealed by analysis of IgVH gene hypermutation and lineage trees

Agerelated differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity

Evolution of antibody immunity to SARS-CoV-2. bioRxiv

Acknowledgement: We thank Ms. Elisabeth Vetter, Euroimmun, for her support and help and Euroimmun, Lübeck, Germany. We thank Bianca Neurauter for excellent assistance when organizing the study and Lisa-Maria Raschbichler and Albert Falch for excellent technical support.

A c c e p t e d M a n u s c r i p t 10 A c c e p t e d M a n u s c r i p t 15